In this context, we have already designed pharmacological strategies for inhibiting MACC1 by the small‐molecule transcriptional inhibitors lovastatin or rottlerin for CRC (Juneja et al., 2017). This evidence concerns the gene MACC1 and colorectal carcinoma.